Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Nilsson

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Child and Adolescent Psychopharmacology|November 6, 2007
Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placeboSitra Tauscher-Wisniewski, Mary Nilsson, Cathy Caldwell, et al.
British Journal of Pharmacology|November 18, 2009
Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signallingFui Goon Goh, Pei Yuen Ng, Mary Nilsson, et al.
Current Medical Research and Opinion|September 30, 2010
Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-analysisAntonio Crucitti, Qi Zhang, Mary Nilsson, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19Mary Nilsson, Brenda Crowe, Greg Anglin, et al.
Journal of Child and Adolescent Psychopharmacology|January 15, 2005
Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescentsMary Nilsson, Melissa J Joliat, Cherri M Miner, et al.
Cellular Signalling|April 22, 2008
G-protein-dependent and -independent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytesFui Goon Goh, Callum M Sloss, Margaret R Cunningham, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
Reference Limits for Outlier Analyses in Randomized Clinical TrialsCharles M Beasley, Brenda Crowe, Mary Nilsson, et al.
Journal of Biopharmaceutical Statistics|February 14, 2019
Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methodsCharles M Beasley, Brenda Crowe, Mary Nilsson, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 5, 2002
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trialGraham J Emslie, John H Heiligenstein, Karen Dineen Wagner, et al.
The Journal of Biological Chemistry|March 14, 2012
Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4)Margaret R Cunningham, Kathryn A McIntosh, John D Pediani, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Child and Adolescent Psychopharmacology|November 6, 2007
Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placeboSitra Tauscher-Wisniewski, Mary Nilsson, Cathy Caldwell, et al.
British Journal of Pharmacology|November 18, 2009
Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signallingFui Goon Goh, Pei Yuen Ng, Mary Nilsson, et al.
Current Medical Research and Opinion|September 30, 2010
Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-analysisAntonio Crucitti, Qi Zhang, Mary Nilsson, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19Mary Nilsson, Brenda Crowe, Greg Anglin, et al.
Journal of Child and Adolescent Psychopharmacology|January 15, 2005
Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescentsMary Nilsson, Melissa J Joliat, Cherri M Miner, et al.
Cellular Signalling|April 22, 2008
G-protein-dependent and -independent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytesFui Goon Goh, Callum M Sloss, Margaret R Cunningham, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
Reference Limits for Outlier Analyses in Randomized Clinical TrialsCharles M Beasley, Brenda Crowe, Mary Nilsson, et al.
Journal of Biopharmaceutical Statistics|February 14, 2019
Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methodsCharles M Beasley, Brenda Crowe, Mary Nilsson, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 5, 2002
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trialGraham J Emslie, John H Heiligenstein, Karen Dineen Wagner, et al.
The Journal of Biological Chemistry|March 14, 2012
Novel role for proteinase-activated receptor 2 (PAR2) in membrane trafficking of proteinase-activated receptor 4 (PAR4)Margaret R Cunningham, Kathryn A McIntosh, John D Pediani, et al.
Pageof 1